EntreChem data on the first family of antitumoral molecules being developed by the company have been selected for a poster presentation at the 20th ENA symposium held in Geneva from 21-24 October 2008. The principal investigator is Dr. Carlo Catapano, from the Istituto Oncologico della Svizzera Italiana (IOSI) in Bellinzona (Switzerland) and the title of the Abstract approved by the Scientific Committee is “In vitro and in vivo antitumor activity of novel aureolic acid analogues generated by metabolic engineering of the biosynthetic pathways in Streptomyces argillaceus and Streptomyces griseus subsp. griseus”.
The poster will show pharmacokinetic and mechanism of action data, as well as efficacy proof of concept of certain mitramycin analogs obtained by combinatorial biosynthesis on mice xenograft of human colon, prostate and melanoma tumor models. The poster Session will take place on October 22th, 2008.
About EORTC-NCI-AACR symposium: Hosted by EORTC (European Organisation for Research and Treatment of Cancer), NCI (National Cancer Institute) and AACR (American Asociation for Cancer Research), the symposium, ‘Molecular Targets and Cancer Therapeutics’ brings together academics, scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology of cancer. For more information visit Congress and Conferences Section at: www.ecco-org.eu
About EntreChem SL: EntreChem is a start-up company founded as a spin-off of the University of Oviedo in 2005 by Prof. Vicente Gotor, Prof. José A. Salas and Francisco Morís, Ph.D. The company focuses on novel products obtained by biocatalysis and combinatorial biosynthesis approaches, as well as development of processes involving enzymatic catalysis and genetic engineering of metabolic pathways. More information can be found at www.entrechem.com
